Supplementary Materialsoncotarget-10-133-s001. and effector functions of RasGRF2 underlie at least in part, the AnxA6 mediated TNBC cell growth and/or motility, but also provide a rationale to target Ras-driven TNBC with EGFR targeted therapies in combination with inhibition of RasGRF2. = 8). EZR The growth of the xenograft AR-C69931 enzyme inhibitor tumors was monitored over time… Continue reading Supplementary Materialsoncotarget-10-133-s001. and effector functions of RasGRF2 underlie at least in